MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

phase 3 clinical trial

  • Home
  • phase 3 clinical trial
Efficacy and Safety of Ecopipam for Tourette Syndrome: Phase 3 Randomized Clinical Trial
Posted inNeurology news Pediatrics

Efficacy and Safety of Ecopipam for Tourette Syndrome: Phase 3 Randomized Clinical Trial

Posted by By MedXY 06/05/2026
This phase 3 trial found that ecopipam reduced tic relapse and maintained symptom improvement in children and adolescents with Tourette syndrome, with mainly central nervous system side effects and no major weight or metabolic concerns.
Read More
Gedatolisib Demonstrates Promising Efficacy in Phase 3 VIKTORIA-1 Trial for HR+/HER2- Advanced Breast Cancer: NDA Submission Initiated
Posted inOncology

Gedatolisib Demonstrates Promising Efficacy in Phase 3 VIKTORIA-1 Trial for HR+/HER2- Advanced Breast Cancer: NDA Submission Initiated

Posted by By MedXY 10/24/2025
Celcuity's phase 3 VIKTORIA-1 trial reveals that gedatolisib, a broad-spectrum PI3K/mTORC1/2 inhibitor, significantly improves progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer patients post CDK4/6 inhibitor therapy, prompting NDA rolling submission.
Read More
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Haemoglobinuria: 48-Week Outcomes from APPLY-PNH and APPOINT-PNH Phase 3 Trials
Posted inClinical Updates Internal Medicine news Pediatrics Specialties

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Haemoglobinuria: 48-Week Outcomes from APPLY-PNH and APPOINT-PNH Phase 3 Trials

Posted by By MedXY 08/03/2025
Oral iptacopan provides sustained haemolysis control and improved haemoglobin in PNH patients over 48 weeks, with a favorable safety profile, supporting its role as a new therapeutic option.
Read More
  • NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple Myeloma
  • Refining Right Ventricular Assessment in Pulmonary Hypertension: Impact of Postprocessing Techniques on Cardiac MRI Metrics
  • Decoding Persistent Tachypnea of Infancy: Genetic Insights Expand Diagnostic Paradigms
  • Mechanical Ventilation-Induced Neutrophil Extracellular Vesicles: A Novel Mediator in Postoperative Pulmonary Complications
  • Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian Cohort
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top